NO116120B - - Google Patents
Info
- Publication number
- NO116120B NO116120B NO16050065A NO16050065A NO116120B NO 116120 B NO116120 B NO 116120B NO 16050065 A NO16050065 A NO 16050065A NO 16050065 A NO16050065 A NO 16050065A NO 116120 B NO116120 B NO 116120B
- Authority
- NO
- Norway
- Prior art keywords
- parts
- acid
- isoxazole
- weight
- volume
- Prior art date
Links
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- -1 3,5-disubstituted isoxazole compounds Chemical class 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- SKISYMYDQIWNBM-UHFFFAOYSA-N 1-(1,2-oxazol-3-yl)ethanone Chemical compound CC(=O)C=1C=CON=1 SKISYMYDQIWNBM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 229920002866 paraformaldehyde Polymers 0.000 description 8
- 229930040373 Paraformaldehyde Natural products 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- UWBLJVQLPPKWSO-UHFFFAOYSA-N 1-(5-phenyl-1,2-oxazol-3-yl)ethanone Chemical compound O1N=C(C(=O)C)C=C1C1=CC=CC=C1 UWBLJVQLPPKWSO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 3
- CTRFFTPRQSZVLD-UHFFFAOYSA-N 1-(3-phenyl-1,2-oxazol-5-yl)-3-piperidin-1-ylpropan-1-one Chemical compound C1(=CC=CC=C1)C1=NOC(=C1)C(CCN1CCCCC1)=O CTRFFTPRQSZVLD-UHFFFAOYSA-N 0.000 description 2
- SOHVRTPQGGXAQS-UHFFFAOYSA-N 1-(3-phenyl-1,2-oxazol-5-yl)ethanone Chemical compound O1C(C(=O)C)=CC(C=2C=CC=CC=2)=N1 SOHVRTPQGGXAQS-UHFFFAOYSA-N 0.000 description 2
- UELTWNRRPXPRQT-UHFFFAOYSA-N 1-(5-phenyl-1,2-oxazol-3-yl)-3-piperidin-1-ylpropan-1-one Chemical compound N1(CCCCC1)CCC(=O)C1=NOC(=C1)C1=CC=CC=C1 UELTWNRRPXPRQT-UHFFFAOYSA-N 0.000 description 2
- CIQJWKNJDQKPPO-UHFFFAOYSA-N 1-chloropiperidine Chemical compound ClN1CCCCC1 CIQJWKNJDQKPPO-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- VGVJBKVOTSFQDX-UHFFFAOYSA-N 3-morpholin-4-yl-1-(3-phenyl-1,2-oxazol-5-yl)propan-1-one Chemical compound C1(=CC=CC=C1)C1=NOC(=C1)C(CCN1CCOCC1)=O VGVJBKVOTSFQDX-UHFFFAOYSA-N 0.000 description 2
- ILNGCUVXLQVDTC-UHFFFAOYSA-N 4-chloromorpholine Chemical compound ClN1CCOCC1 ILNGCUVXLQVDTC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XDRMBCMMABGNMM-UHFFFAOYSA-N ethyl benzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=CC=C1 XDRMBCMMABGNMM-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 2
- CZXGXYBOQYQXQD-UHFFFAOYSA-N methyl benzenesulfonate Chemical compound COS(=O)(=O)C1=CC=CC=C1 CZXGXYBOQYQXQD-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RNSGBYUFHBXKPU-UHFFFAOYSA-N 1-chloropyrrolidine Chemical compound ClN1CCCC1 RNSGBYUFHBXKPU-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- VRVWHTHWKHVLNC-UHFFFAOYSA-N 3-morpholin-4-yl-1-(5-phenyl-1,2-oxazol-3-yl)propan-1-one Chemical compound O1CCN(CC1)CCC(=O)C1=NOC(=C1)C1=CC=CC=C1 VRVWHTHWKHVLNC-UHFFFAOYSA-N 0.000 description 1
- BXQDLEHCXQQSCH-UHFFFAOYSA-N 5-phenyl-1,2-oxazole Chemical compound O1N=CC=C1C1=CC=CC=C1 BXQDLEHCXQQSCH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- HJMZBNMKFYKPJM-UHFFFAOYSA-N C1(=CC=CC=C1)C1=NOC(=C1)C(CCN1CCCC1)=O Chemical compound C1(=CC=CC=C1)C1=NOC(=C1)C(CCN1CCCC1)=O HJMZBNMKFYKPJM-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IDCHQQSVJAAUQQ-UHFFFAOYSA-N N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine Chemical compound O1C(CCN(CC)CC)=NC(C=2C=CC=CC=2)=N1 IDCHQQSVJAAUQQ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960003625 oxolamine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Fremgangsmåte for fremstilling av nye terapeutisk aktive j5,5-disubstituerte isoksazolderivater.
Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av nye, terapeutisk aktive 3,5-disub'stituerte isokaazolf orbindelser med den generelle formel I
og farmakologisk tålbare salter derav, hvori gruppen utgjør en pyrrolidino-, piperidino- eller morfolinogruppe og hvori' de to substituente.r på isoksazolringeit befinner seg i henhv. 3-og 5-stillingene, og det særegne ved fremgangsmåten i henhold til oppfinnelsen er at et acetyl-isoksazol med formel II
hvori de to substituenter på isoksazolringen befinner seg i henhv. 3- og 5-stillingene, omsettes med formaldehyd og pyrrolidin, piperidin eller morfolin, eller et syreaddisjonssalt derav, hvor-etter eventuelt den erholdte forbindelse overføres til et salt.
Oppfinnelsen angår således en fremgangsmåte for fremstilling av 3,5-disubstituerte isoksazolderivater med strukturformler: hvori gruppen
har den ovennevnte betydning.
Utga.ngsacetylisoksazol-forbindelsene utgjøres av 3-acetyl-5-fenylisoksazol, henhv. 3-£enyl-5-acetylisoksazol. Som det a-tinet utgangsmaterial anvendes pyrrolidin, piperidin eller morfolin.
Disse heterocykliske forbindelser kan anvendes i form av et syreaddisjonssalt valgt fra. gruppen bestående av hydroklorid, hydrobromid, hydrojodid og sulfatet. Videre kan formaldehyd anvendes i gassform, i vandig oppløsning (formalin) eller som paraformaldehyd.
Omsetningen av acetylisoksazolet med formaldehyd og pyrrolidin, piperidin eller morfolin, eller dets syreaddisjonssalter derav, kan utføres i et inert oppløsningsmiddel innenfor et vidt temperaturområde av fra. ca. 2Q°C (romtemperatur) til tilbakeløpstemperatur, fortrinnsvis i nærvær av en syre. Som inert oppløsningsmiddel anvendes som reaksjonsmedium f.eks. metanol, etanol, propanol, eter, dipropyleter, tetrahydrofuran, dioksan og lignende ut fra betraktninger om opp-' løseligheten av materialene. Eksempler på de syrer som fortrinnsvis anvendes er uorganiske syrer som saltsyre, bromhydrogensyre, jod-hydrogensyre, svovelsyre, fosforsyre og perklorsyre eller organ^i|ijke syrer som eddiksyre, metansulfonsyre, benzensulfonsyre og p-toluen-sulfonsyre.
Spesifikke eksempler på de 3,5-disubstituerte isoksazolderivater
som kan fremstilles ved den foreliggende fremgangsmåte er 3-(3-piperidinopropionyl)-5-f enylisoksazol, 3-0-morf olinopropionyl)-5-fenylisoksazol, 3-fenyl-5-(3-piperidino-propionyl)-isoksazol og 3-fenyl-5-(3-morfolinopropionyl)-isoksazol.
De ved hjelp av foreliggende fremgangsmåte fremstillbare 3.5-disubstituerte isoksazolderivater er flytende eller faste i fri til-stand. For hensiktsmessig fremstilling kan de omdannes til sine sijreaddis jons sal ter eller kvartære salter, f. eks. ved å behandle baser med en syre som f.eks. saltsyre, bromhydrogensyre, jod-hydrogensyre, svovelsyre, salpetersyre, fosforsyre, tiocyansyre, karbonsyre, eddiksyre, propionsyre, oksalsyre, sitronsyre, ravsyre, salicylsyre, benzosyre eller palmitinsyre eller en forbindelse som danner kvartøre forbindelser, som f.eks. metylklorid, etylklorid, etylbromid, metyljodid, etyljodid, fenetylbromid, metylbenzensulfonat, etylbenzensulfonat eller metyl-p-toluensulfonat i et passende oppløsningsmiddel som f.eks.vann, metanol, etanol, eter, benzen eller toluen. Det fremstilles således det tilsvarende hydrokloridj hydrobromidjhydrojodid, sulfat, nitrat, fosfat, tiocyanat, karbonat, acetat, propionat, oksalat,•citrat, tartrat, suksinat, salicylat, benzoat eller palmitat, eller det tilsvarende metylklorid, metyl-bromid, metyljodid, etylbromid, etyljodid, metylbenzensulfonat, etylbenzensulfonat eller metyl-p-toluensulfonat.
De 3,5-disubstituerte isoksazolderivater med formel (I) og ikke-giftige salter derav er nyttige som antipyretiske, analgetiske, antitussive og antiinflammatoriske midler. De kan administreres på en rekke forskjellige i og for seg vanlige måter, f.eks. i form av tabletter som utgjøres f.eks. av en effektiv enkelt dose av aktiv forbindelse og en hovedandel av en vanlig bærer.
Den følgende tabell illustrerer forbindelsenes farmakologiske virkninger.
Det sees av de følgende tabelldata at de foreliggende forbindelser er klart overlegne den tidligere kjente forbindelse, dvs. oksolamin, spesielt med hensyn til antipyretisk og antiflammatorisk aktivitet.
De følgende eksempler representerer forskjellige utførelsesformer
for fremgangsmåten i henhold til oppfinnelsen, og vektdeler i disse eksempler har samme forhold til volumdeler som gram til milliliter.
Eksempel 1. 3-fen^l-5-^3-£i£eridinogro£ion^l)-isoksazol
En blanding av.3-fenyl-5-acetylioksazol (187 vektdeler), piperidino-hydroklorid (122 verktdeler), paraf ormaldehyd (45 vektdeler), konsentrert saltsyre (3 volumdeler), og dioksan (300 volumdeler) kokes under til-bakeløp i 1 time. Til reaksjonsblandingen tilsettes aceton og det avkjøles med is. Den utfelte substans oppsamles ved filtrering, vaskes med aceton og oppløses i vann. Den resulterende oppløsning gjøres alkalisk og ekstraheres med eter. Ekstrakten vaskes med eter,
tørres over vannfritt kaliumkarbonat og konsentreres. Resten krystalliseres fra. petroleter og gir 3-fenyl-5-(3-piperidinopropionyl)-isoksazol (176 vektdeler), som farveløse plater som smelter ved 93-94°G.
Analyse beregnet for C17<H2>002<N>2<:>C, 71,80; H, 7,09; N, 9.85.
Funnet: 8, 71.87; H, 7.31; N, 9.88.
Hydrokloridet utgjøres av farveløse plater som smelter ved 195-196°C når dp krystalliseres fra 95$ vannholdig eter.
Analyse beregnet for C17<H2>002N2.HC1: 0, 63,64; H, 6.60; N, 8.73; Funnet: C, 63,47; H. 6,68; N, 8,58.
Eksempel 2: 3^<fe>ny^-5-O-morfolinog<ro>giony^-isoksazol
En blanding av 3-fenyl-5-acetylisoksazol (187 vektdeler), morfolino-hydroklorid (124 vektdeler), paraformaldehyd (45 vektdeler), konsentrert saltsyre (3 volumdeler) og vannfri etanol (300 volumdeler) kokes under tilbakeløp i 3 timer. Reakajonsblandingen behandles på lignende måte som i eksempel 1, og de resulterende rå krystaller omkrystalliseres fra ligroin og gir 3-fenyl-5-(3-morfolino-propionyl)-isoksazol (57 vektdeler) som farveløse prismer som smelter ved 103-105°0.
Analyse beregnet for C16H1805N2: C, 67,11; H, 6,34; N, 9,78.
Funnet: C, 67,61; H, 6,54; N, 9,28.
Eksempel 3: 3-fen^l-5-^3-p£rrolidino£ropion^
En blanding av 3-fenyl-5-acetylisoksazol (187 vektdeler), pyrrolidino-hydroklorid (110 vektdeler), paraformaldehyd (45 vektdeler), kon^sentrert saltsyre (3 volumdeler) og vajxnfri etanol (300 volumdeler) kokes under tilbakeløp i 3 timer. Reaksjonsblåndingen behandles på lignende måte som i eksempel 1, og de resulterende rå krystaller omkrystalliseres fra petroleter og gir 3-fenyl-5-(3-pyrrolidinopropio-nyl)-isoksazol (48 vektdeler) som blekgule prismer som smelter ved 81-82°C.
Analyse beregnet for C^H^OgNg: C, 71,09; H, 6,71; N, 10,36. Funnet: C, 71.36; H, 6,88; H, 10,11.
Hydrokloridet utgjøres av farveløse nåler som smelter ved 164-165°C når de krystalliseres fra etanol.
Analyse beregnet for C^<H>^OgNg.HOl: C, 62,64; H, 6,24; N, 9,13; Funnet: C, 61.97; H, 6,45; N, 893.
Eksempel 4: 3-X3-£igeridinopro£ion^l)-5-fenylisoksazol En blanding av 3-acetyl-5-fenylisoksazol (375 vektdeler), piperidino-hydroklorid (243 vektdeler), paraformaldehyd (90 vektdeler), konsentrert saltsyre (5 volumdeler) og dioksan (600 volumdeler) oppvarmes under tilbakeløp. Etter 1 time tilsettes paraformaldehyd (45 vektdeler) og kokingen under tilbakeløp fortsettes 2 timer. Reaksjonsblandingen behandles på lignende måte som i eksempel 1,
og de rå krystaller omkrystalliseres fra petroleter og gir 3-(3-piperidinopropionyl)-5-fenylisoksazol (360 vektdeler) som krystaller som smelter ved 93-96,5°C.
Analyse beregnet for C17<H2>002N2: C, 71,80; H, 7,09; N, 9,85.
Funnet: G, 71,93; H, 8,10; N, 9,64.
Eksempel 5: 5-O-morfolinogrogion^l)5-fenylisoksazol
fin blanding av 3-acetyl-5-fenylisoksazol (375 vektdeler), morfolino-hydroklorid (659 vektdeler), paraformaldehyd (240 vektdeler),
konsentrert saltsyre (159 volumdeler) og vannfri etanol (600 volum-'
deler) oppvarmes under tilbakeløp. Etter 1 time tilsettes paraform-
aldehyd (120 volumdeler) og kokingen under tilbakeløp fortsettes i 2 timer. Reaksjonsblandingen behandles på lignende måte som i eksempel 1, og de rå krystaller omkrystalliseres fra ligroin og gir 3-(3-morfolinopropionyl)-5-fenyl—isoksazol (743 vektdeler) som krystaller som smelter ved 111,5-113°0.
Analyse beregnet for G16<H>18<0>3<N>2<:>C, 67,11; H, 6,34; N, 9,78.
Funnet C, 67,20; H, 6,43; N, 9,59.
Claims (1)
- Fremgangsmåte for fremstilling av nye, terapeutisk aktive 3,5-disubstituerte isoksazolforbindelser med den generelle formelog farmakologisk tålbare salter derav, hvori gruppen utgjør en pyrrolidino, piperidino- eller morfolinogruppe og hvori de to substituenter på isoksazolringen befinner seg i henhv. 3-og 5-stillingene,karakterisert vedat et acetyl-isoksazol med formelhvori de to substituenter på isoksazolringen befinner seg i henhv. 3- og 5-stillingene, omsettes med formaldehyd og pyrrolidin, piperidin eller morfolin, eller et syreaddisjonssalt derav,.hvor-etter eventuelt den erholdte forbindelse overføres til et salt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6564964 | 1964-11-20 | ||
JP5095665 | 1965-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO116120B true NO116120B (no) | 1969-02-03 |
Family
ID=26391453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO16050065A NO116120B (no) | 1964-11-20 | 1965-11-16 |
Country Status (9)
Country | Link |
---|---|
BR (1) | BR6575006D0 (no) |
CH (1) | CH472420A (no) |
DE (1) | DE1620324A1 (no) |
DK (2) | DK124614B (no) |
FR (1) | FR4869M (no) |
GB (1) | GB1101158A (no) |
NL (1) | NL148052B (no) |
NO (1) | NO116120B (no) |
SE (1) | SE336337B (no) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6034546B2 (ja) * | 1978-03-09 | 1985-08-09 | 大鵬薬品工業株式会社 | グリオキサ−ル−2−オキシム誘導体及びその製造方法 |
US4929630A (en) * | 1986-03-14 | 1990-05-29 | Syntex (U.S.A.) Inc. | Transglutaminase inhibitors |
US4912120A (en) * | 1986-03-14 | 1990-03-27 | Syntex (U.S.A.) Inc. | 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors |
-
1965
- 1965-11-12 GB GB48081/65A patent/GB1101158A/en not_active Expired
- 1965-11-16 NO NO16050065A patent/NO116120B/no unknown
- 1965-11-19 BR BR17500665A patent/BR6575006D0/pt unknown
- 1965-11-19 DE DE19651620324 patent/DE1620324A1/de active Pending
- 1965-11-19 CH CH1596065A patent/CH472420A/de not_active IP Right Cessation
- 1965-11-19 FR FR39058A patent/FR4869M/fr not_active Expired
- 1965-11-19 SE SE1498665A patent/SE336337B/xx unknown
- 1965-11-20 DK DK597065A patent/DK124614B/da unknown
- 1965-11-22 NL NL656515145A patent/NL148052B/xx unknown
-
1966
- 1966-09-21 DK DK48666A patent/DK114061B/da unknown
Also Published As
Publication number | Publication date |
---|---|
DK124614B (da) | 1972-11-06 |
FR4869M (no) | 1967-02-27 |
DK114061B (da) | 1969-05-27 |
GB1101158A (en) | 1968-01-31 |
NL148052B (nl) | 1975-12-15 |
SE336337B (no) | 1971-07-05 |
BR6575006D0 (pt) | 1973-09-06 |
CH472420A (de) | 1969-05-15 |
NL6515145A (no) | 1966-05-23 |
DE1620324A1 (de) | 1970-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU685225B2 (en) | Novel carbamate derivative and medicinal composition containing the same | |
Turner et al. | Studies on imidazole compounds. I. 4-Methylimidazole and related compounds | |
EP0040639A1 (en) | Isoxazole derivatives | |
DE2245159A1 (de) | Stickstoffhaltige heterocyclische verbindungen | |
US3462444A (en) | Novel 4-benzylpiperidine derivatives | |
US3478032A (en) | N-substituted-n'-aryl diazacycloalkanes | |
US3456060A (en) | Therapeutic compositions containing piperidine derivatives and methods of treating cough and pain therewith | |
US2872453A (en) | Indole derivatives | |
EP0089028A1 (de) | Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung | |
AU4473397A (en) | Novel terephthalamide derivatives | |
NO116120B (no) | ||
US2694705A (en) | Nx c c ox a a | |
US3381013A (en) | Heterocyclicamino ethers of benzylphenols | |
US2704757A (en) | 5-hydroxy-3, 4, 5, 6-tetrahydropyriminines | |
JP2931986B2 (ja) | アラルキルアミン誘導体 | |
NO141160B (no) | Analogifremgangsmaate til fremstilling av terapeutisk virksomme 3,4-dihydro-2(1h)-isokinolinkarboksamider | |
US3452026A (en) | Substituted 1,2,3,4-tetrahydroquinolines | |
US2485662A (en) | Alpha-(aminoalkyl)-stilbenes | |
US3340268A (en) | 1-[piperidyl]-2, 2-di(monocyclic hexacyclic aryl)-cyclopropane | |
US3374245A (en) | Unsaturated oxacycles | |
US3147268A (en) | 4-amino derivatives of methylpiperidines | |
US3936459A (en) | 1',4'-Dihydro-1-methyl-spiro [piperidine and pyrrolidine-2,3'(2'H)quinoline]-2'-one compounds | |
US3324139A (en) | 3-(3-hydroxyphenyl)-1-phenacylpiperidine compounds | |
US3974282A (en) | Hypoglycemic stilbazolte derivatives | |
US3969356A (en) | N-[3-(p-f-benzoyl)-propyl]-N'-[2.(nitro,nitro-el, or methoxyphenyl)-ethyl]-p |